# 8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

> **NCT00230581** · PHASE2 · COMPLETED · sponsor: **Dynogen Pharmaceuticals** · enrollment: 88 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** DDP225

## Key facts

- **NCT ID:** NCT00230581
- **Lead sponsor:** Dynogen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2007-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230581, "8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00230581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*